Hepatocellular carcinoma is a common and highly aggressive tumor that has been recognized as the seventh most common malignancy and the fourth leading cause of cancer-related death worldwide. Although clinical treatment of hepatocellular carcinoma has made great strides in recent decades, including radical resection, interventional therapy, liver transplantation to targeted therapy or immunotherapy, the estimated 5-year survival rate remains low at 14-18% due to its occult and aggressive nature. Therefore, efforts are being made to further improve our understanding of the molecular pathogenesis of liver cancer with a view to developing new therapeutic strategies to reduce the mortality of this malignancy.

Pre: On July 14, Bojian's listing application for tofersen injection was accepted.

Next: Bagel Biologics receives approval to initiate Phase I clinical trial of TCR cell therapy